Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17052738 | 0.83 | POLB (0.53) | POLBTSHRLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL17045890 | 0.77 | POLB (0.50) | POLBTSHRLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4558544 | 0.77 | CFTR (0.60) | POLBTSHRLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL8458374 | 0.76 | POLB (0.53) | POLBTSHRLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5476527 | 0.75 | POLB (0.56) | POLBTSHRLMNAALDH1A1SMN1; SMN2 | |
| Potassium Ion SCHEMBL28864278 | 0.74 | POLB (0.54) | POLBTSHRLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL776536 | 0.73 | NPSR1 (0.49) | TSHRLMNAALDH1A1CFTRNPSR1 | |
| SCHEMBL10666125 | 0.73 | POLB (0.49) | POLBTSHRLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5743094 | 0.72 | TBXAS1 (0.48) | POLBTSHRLMNAALDH1A1KDM4E | |
| SCHEMBL16772448 | 0.71 | LMNA (0.49) | POLBTSHRLMNAALDH1A1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478594-B2 | Methods of treatment of kidney injury associated with infection or trauma | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220226266-A1 | Methods of Treatment of Kidney Injury Associated with Infection or Trauma | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-21 | — | — | US | disclosed |
| WO-2020240524-A2 | METHODS OF TREATMENT OF KIDNEY INJURY ASSOCIATED WITH INFECTION OR TRAUMA | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-12-03 | — | — | WO | disclosed |
| US-10233201-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburg—Of the Commonwealth System of Higher Education (US) | 2019-03-19 | — | — | US | disclosed |
| US-10233201-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburg—Of the Commonwealth System of Higher Education (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170320898-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2017-11-09 | — | — | US | disclosed |
| US-20170320898-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2017-11-09 | — | — | US | disclosed |
| US-20170320898-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2017-11-09 | — | — | US | disclosed |
| US-9670236-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670236-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670236-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150246939-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-09-03 | — | — | US | disclosed |
| US-20150246939-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-09-03 | — | — | US | disclosed |
| US-20150246939-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233201-B2 | Class of HDAC inhibitors expands the renal progenitor cells population and improves the rate of recovery from acute kidney injury | HDAC1, HDAC9, HDAC11 | POLB 1451/4885TSHR 3966/4885LMNA 1928/4885 |
| US-20220226266-A1 | Methods of Treatment of Kidney Injury Associated with Infection or Trauma | MMP8, PLAU, KLKB1 | POLB 3346/4885TSHR 2955/4885LMNA 2370/4885 |
| US-20150246939-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | HDAC1, HDAC9, HDAC11 | POLB 1451/4885TSHR 3966/4885LMNA 1928/4885 |
| US-12478594-B2 | Methods of treatment of kidney injury associated with infection or trauma | HDAC1, HDAC2, HDAC4 | POLB 1270/4885TSHR 3486/4885LMNA 2466/4885 |
| US-20170320898-A1 | Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury | HDAC1, HDAC9, HDAC11 | POLB 1451/4885TSHR 3966/4885LMNA 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.